AbbVie expands blood cancer portfolio with recent FDA nod (opens in new tab)

New approval for ultra-rare blood cancer highlights the growing role of precision therapies in treating age-related disease. One of the greatest challenges in longevity is ensuring people can survive the diseases that become more common with age. Cancer remains one of the biggest obstacles to extending healthy lifespan, and while much of the spotlight falls […] The post appeared first on <a href="